Apimeds Pharmaceuticals US (APUS) Capital Expenditures (2025)

Apimeds Pharmaceuticals US (APUS) posted Capital Expenditures of $21424.0 for Q4 2025, down 4.95% on a QoQ basis from $22540.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Capital Expenditures (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Capital Expenditures history runs 1 years deep, the most recent figure standing at $21424.0 for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	168.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	110.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	1.95 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	99.60 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	39.90 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	1.40 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	51.00 Mn
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-	21,424.00

Download Data